Monocyte-derived macrophages orchestrate tissue regeneration by homing to sites of injury, phagocytosing pathological debris, and stimulating other cell types to repair the tissue. Accordingly, monocytes have been investigated as a translational and potent source for cell therapy, but their utility has been hampered by their rapid acquisition of a pro-inflammatory phenotype in response to the inflammatory injury microenvironment. To overcome this problem, we designed a cell therapy strategy where we collect and exogenously reprogram monocytes by intracellularly loading the cells with biodegradable microparticles containing an anti-inflammatory drug in order to modulate and maintain an anti-inflammatory phenotype over time. To test this concept, poly(lactic-co-glycolic) acid microparticles were loaded with the anti-inflammatory drug dexamethasone (Dex) and administered to primary human monocytes for four hours to facilitate phagocytic uptake. After removal of non-phagocytosed microparticles, microparticle-loaded monocytes differentiated into macrophages and stored the microparticles intracellularly for several weeks in vitro, releasing drug into the extracellular environment over time. Cells loaded with intracellular Dex microparticles showed decreased expression and secretion of inflammatory factors even in the presence of pro-inflammatory stimuli up to 7 days after microparticle uptake compared to untreated cells or cells loaded with blank microparticles. This study represents a new strategy for long-term maintenance of anti-inflammatory macrophage phenotype using a translational monocyte-based cell therapy strategy without the use of genetic modification. Because of the ubiquitous nature of monocytederived macrophage involvement in pathology and regeneration, this strategy holds potential as a treatment for a vast number of diseases and disorders.
INTRODUCTION
Tissue regeneration, essential for healing and restoring damaged organs following trauma or disease, is driven by the innate immune system 1, 2 . In particular, monocytederived macrophages coordinate multiple aspects of tissue regeneration by homing to sites of injury 3, 4 , phagocytosing pathogenic or necrotic material 5, 6 , secreting factors that drive regeneration 7, 8 , and regulating the behavior of other cells involved in tissue regeneration, including endothelial cells, fibroblasts, and stem cells [8] [9] [10] [11] [12] [13] . Because monocyte-derived macrophages are master regulator cells overseeing tissue regeneration across a number of pathologies, and because monocytes can be readily isolated from peripheral blood, monocytes are an ideal cell source for translational treatments. In fact, the administration of monocytes or macrophages has shown promise in many studies across a range of diseases and tissue injury situations 14 .
First explored in the 1970s as a cancer treatment strategy, monocytes and macrophages have been administered in a number of completed and ongoing clinical trials as a cell therapy for ovarian cancer [NCT02948426], pressure ulcers 15 , spinal cord injury 16 , ischemic stroke 17 , and renal transplant rejections 18 . In these clinical trials, administration of monocytes or macrophages did not result in severe adverse events, suggesting a high level of safety in administering monocyte/macrophage-based therapies 14, 17 . However, the efficacy of monocyte/macrophage-based therapies has been limited, in large part because macrophages are highly plastic cells that quickly change their behavioral phenotype depending upon microenvironmental stimuli 19 . It is currently not possible to harness the regenerative potential of macrophages because they only transiently induce the desired behavioral pattern before taking on a detrimental phenotype at the site of injury 14, 20, 21 . For example, when macrophages were polarized to a regenerative phenotype prior to administration into a preclinical model of spinal cord injury in mice, the regenerative macrophages lost this phenotype within 3 days 20 . Likewise, administration of anti-inflammatory macrophages into a murine model of adriamycin nephropathy lost their anti-inflammatory phenotype within 2 days and upregulated markers of inflammation within 7 days 21 . In contrast, strategies to control macrophage phenotype via gene editing have shown promise but require further development due to generally non-specific -and potentially detrimental -insertion sites of genetic material into the host genome, low transfection rate, and increased immunogenicity of genetically edited cells 22, 23 . Clearly, there is a need to develop a strategy to promote and sustain an anti-inflammatory phenotype in monocyte-derived macrophages in order to harness their beneficial effects without amplifying local inflammation.
Our overall strategy is to leverage the high therapeutic potential and exceptional behavioral plasticity of monocyte-derived macrophages to mitigate inflammation and promote regeneration following injury. In order to reprogram macrophages and overcome design limitations of previous strategies, such as transient polarization and non-specific targeting, we devised a cell therapy strategy that is selectively administered to monocytes and controls macrophage phenotype over time through the use of intracellular biomaterials. In this strategy, monocytes would be isolated from patients, incubated with drug-loaded microparticles to allow phagocytic uptake, and then re-administered back into the patient either systemically or locally, so that the intracellular release of drug can subsequently modulate inflammation and promote regeneration following injury (Fig. 1) .
The goal of this study was to characterize the ability of this system to control macrophage phenotype in vitro for up to 7 days following microparticle uptake.
For proof of concept, we utilized the anti-inflammatory glucocorticoid dexamethasone (Dex) because it down-regulates transcription of inflammatory cytokines [24] [25] [26] [27] and simultaneously enhances functions associated with regeneration such as homing [27] [28] [29] , phagocytosis 24, 26, 27, 30, 31 , and iron regulation 27, 32, 33 within macrophages.
Additionally, Dex receptors are intracellular, making it an ideal choice for an intracellular particle-based strategy. Dex has been widely used for the treatment of inflammatory diseases, but systemic administration affects a broad number of cells [34] [35] [36] [37] , generating deleterious off-target effects that have contributed to a number of failed preclinical and clinical trials investigating Dex as a translational treatment option [38] [39] [40] . Selective delivery of Dex to the monocyte/macrophage population could hold promising therapeutic advantages by avoiding these off-target effects. Previously, we showed that Dex-loaded microparticles could downregulate inflammatory gene expression of primary human macrophages under non-inflammatory conditions in vitro 26, 27 . Within this study, we analyzed the ability of the microparticles to release drug intracellularly for several weeks and to maintain macrophage phenotype in the presence of inflammatory stimuli for one week in vitro. Because microparticles were rarely observed outside of the cells and because the cell culture media was regularly changed, these results suggest that microparticles remained in the cells at levels that were not detectable via microscopy and released drug into the cell and then extracellularly. Cellular morphology after 43 days of in vitro culture was not affected by treatment with TRITC microparticles ( 
Intracellular Dex Microparticles Release Drug Over Time
PLGA microparticles were fabricated with increasing Dex loading, ranging from 0% to 56% w/w Dex (Sup. Fig. 2A ). Release of Dex from the 33% and the 56% w/w Dex microparticle groups showed a burst release within the first 24 hours followed by a low but steady release of drug for up to 10 days in PBS (Fig. 3A , Sup. Fig. 2A ). Release of Dex from the 2% and 9% w/w Dex microparticle groups exhibited no burst release but exhibited a slow, steady release of drug for more than one week in PBS (Fig. 3A , Sup. 
Intracellular Dex Microparticles Modulate and Maintain Macrophage Phenotype
We next examined the effects of Dex microparticles on expression of receptors associated with phagocytosis and homing, which are critical behaviors in macrophagemediated regeneration. At 7 days after microparticle administration, microparticle-loaded cells upregulated expression of CD163, a surface receptor associated with hemoglobinhaptaglobin scavenging during tissue regeneration [41] [42] [43] , compared to untreated controls, reaching similar levels as those observed in cells treated continuously with free Dex (Fig.   3C ; Sup. Fig. 3 ). Likewise, CCR7, a surface receptor associated with chemotaxis through damaged tissues 44, 45 , was upregulated in cells treated with Dex microparticles relative to untreated controls and cells treated with blank microparticles ( Fig. 3D ; Sup. Fig. 3 ).
MerTK, which is associated with phagocytosis of apoptotic cells and cellular debris 30, 46 , was modestly increased in Dex microparticle-treated cells compared to untreated controls (p<0.07). Contrary to our expectation, we did not observe a significant increase in expression of CCR2, a homing-associated receptor, in cells treated with free Dex or Dex microparticles ( Fig. 3E -F) even though previous literature has shown that Dex upregulates this receptor in macrophages 26, 28, 30 . 
Intracellular Dex Microparticles Modulate Macrophage Phenotype in the Presence of Pro-

Inflammatory Stimuli
Because numerous pathologies are characterized by prolonged inflammation, we next wanted to investigate if the intracellular microparticles could maintain macrophage phenotype even in the presence of inflammatory stimuli. We expected that since Dex was released intracellularly, it could bind to intracellular glucocorticoid receptors and inhibit pro-inflammatory pathways even when cells were cultured in inflammatory environments.
To test this, we administered microparticles with increasing Dex concentrations to monocytes and cultured the particle-loaded cells in inflammatory conditions (complete media supplemented with lipopolysaccharide (LPS) and interferon gamma (IFNγ)) for 7 days. We observed that Dex microparticles caused decreases in the secretion of tumor necrosis factor alpha (TNFα) in a dose-dependent manner ( Fig. 4A-B ). Furthermore, cells treated with microparticles containing high levels of Dex behaved similarly to cells that were continuously treated with free Dex (Fig. 4A-B ).
Intracellular Dex Microparticles Do Not Preclude Phagocytosis
Previous research suggests that Dex administration to macrophages can enhance phagocytosis 24, 47 , but we were curious if pre-loading monocytes with intracellular microparticles would prevent any subsequent phagocytosis. We completed an in vitro functional assay of phagocytosis in the presence of inflammatory stimuli using three different types of targets that an immune cell might encounter: recombinant myelin basic protein, a difficult protein to digest that contributes to pathology following nervous system injury 48, 49 ; E. coli, a common bacterium that macrophages might eliminate from sites of 
Intracellular Dex Microparticles Modulate Inflammation, Phagocytosis, and Homing Genes
We next examined the effects of Dex microparticles on transcription of genes related to inflammation, phagocytosis, homing, and iron metabolism because these genes are modulated by Dex and/or are essential for tissue regeneration 24, 26, 47 . Gene expression data were first assessed with a heatmap where both the rows (representing individual genes) and the columns (representing experimental replicates) were organized with hierarchical clustering (Fig. 5A ). The six experimental replicates within each treatment condition clustered together for all four treatment groups. Cells treated with Dex microparticles were most closely associated with cells that were treated with continuous free Dex (Fig. 5A ). Additionally, cells treated with blank microparticles were most closely associated with the negative control cells that were untreated.
Dex microparticles caused macrophages to downregulate genes associated with inflammation, including NFKB, IL1B, ( Fig 4E-K) . GAS6, a gene associated with phagocytosis, was upregulated in both the blank microparticle group and the Dex microparticle group relative to the free Dex control group (Fig. 5F ).
Considering the published effects of Dex on monocyte homing behavior 28, 29 , we were surprised to find that most of the homing-related genes were not up-regulated in response to free Dex or Dex microparticles ( Fig. 5H-J) . Five of the six homing genes investigated were not significantly different or were downregulated in groups treated with Dex microparticles relative to untreated controls (Sup. Fig. 5A-F ). Both the blank microparticle group and the Dex microparticle group downregulated the homing gene CXCR4 (Fig. 5H) .
In contrast, the free Dex control group and the Dex microparticle group down-regulated PECAM1 expression but up-regulated ITGB2 expression relative to untreated controls and blank microparticle controls ( Fig. 5I-J) . Although previous studies have shown that Dex can modulate some functions associated with iron metabolism 33 and other studies have found that different macrophage phenotypes regulate environmental iron in distinct ways 51 , we observed that administration of free continuous Dex or Dex microparticles did not increase genes related to iron metabolism (Sup. Fig. 5G-J) . In fact, expression of CEPBP, which encodes the CEBPB transcription factor that has been associated with immune and inflammatory responses, was decreased in cells treated with free Dex or Dex microparticles. 
DISCUSSION
The behavioral plasticity of monocyte-derived macrophages allows these cells to play many crucial roles in tissue regeneration, but also poses a challenge in cell therapy because they fail to maintain desirable phenotypes upon administration. In this study, we have demonstrated proof of concept that loading monocytes with drug-loaded biodegradable microparticles can modulate the phenotype of macrophages derived from those monocytes for up to 7 days in vitro. To our knowledge, this study represents the first report of reprogramming of monocytes for sustained maintenance of macrophage phenotype without genetic modification. Taken together with studies that have shown that macrophages can deliver drugs to sites of interest 52, 53 , our findings suggest that microparticle-loaded monocytes hold considerable potential as a cell therapy strategy across a wide range of applications.
In recent years, several landmark studies have shown that the release of immunomodulatory drugs from implanted biomaterials can modulate the behavior of host monocytes and macrophages, with beneficial effects in treating disease and tissue injury 11, [54] [55] [56] [57] . For example, the release of the S1P receptor agonist FTY720 recruits regenerative monocytes and macrophages to promote tissue regeneration [57] [58] [59] .
However, the release of drug from biomaterials may affect all cells in the vicinity, not just macrophages, which may result in off-target effects. Other studies have targeted monocytes by injecting drug delivery vehicles into the blood stream, because circulating monocytes are highly phagocytic 60 . However, in this strategy the majority of nanoparticles and microparticles become sequestered in the liver, lung, spleen, and kidneys, resulting in wasted drug and the potential for side effects in these organs 61 . In addition, the uptake of microparticles by circulating monocytes can inhibit their ability to home to the site of injury, redirecting them to the spleen and causing apoptosis 61 . By loading monocytes with immunomodulatory biomaterials ex vivo and re-administering locally to sites of injury, the disadvantages of off-target effects and reduced homing could be mitigated.
In the present study we showed that some homing genes were downregulated by Dex microparticle treatment while others were upregulated, but these results are likely confounded by the fact that we analyzed the cells after their differentiation into macrophages, which is known to inhibit homing capacity relative to monocytes 62 .
Nonetheless, it is likely that the microparticles would need to be optimized to maintain homing capabilities of monocytes in order for this cell therapy strategy to be utilized as a systemic administration.
Previous literature found that administration of indigestible particles did not prevent macrophage phagocytosis of E. coli or polystyrene beads 63 . Likewise, within this study, we observed that pre-loading cells with Dex microparticles did not preclude any subsequent phagocytosis of targets such as myelin basic protein, E. coli, or polystyrene beads. In the context of gene expression, administering blank microparticles or Dex microparticles generated similar results in several genes, such as CXCR4, TNF, and GAS6, perhaps suggesting that the act of phagocytosing or storing a microparticle intracellularly can modulate macrophage gene expression even in the absence of a therapeutic compound.
The results of this study suggest that intracellular Dex microparticles can modulate and maintain anti-inflammatory macrophage phenotype over time. However, this study is not without limitations. Most importantly, our goal was to assess the capacity of the intracellular microparticles to maintain an anti-inflammatory phenotype of macrophages after 7 days in a highly inflammatory environment in vitro, but the therapeutic benefits of this approach remain to be demonstrated with in vivo models. In particular, the dose of drug, number of microparticles, number of macrophages, and timing of administration will need to be optimized in order to assess a therapeutic effect. Moreover, we chose dexamethasone for proof of concept, but a drug that promotes a more regenerative macrophage phenotype would be a better choice for studying therapeutic efficacy. Finally, within this paper we have not characterized the effect of microparticle-loading on the homing capacity of monocytes, although other groups have completed similar characterizations 52, 53, 62 , but this will be important if monocytes are to be administered systemically.
In conclusion, we demonstrated proof of concept that Dex-loaded microparticles, administered to monocytes, could act intracellularly to modulate and maintain the phenotype of monocyte-derived macrophages for up to one week in vitro. Importantly, this methodology could be utilized as a minimally-invasive, autologous treatment method for a variety of injuries and diseases. Further understanding and advancing tools that modulate immune cell behavior will be instrumental in overcoming detrimental pathology and promoting tissue regeneration across a number of organ systems and disease states.
METHODS
Microparticle Fabrication
Single emulsion poly(lactic-co-glycolic) acid (PLGA) microparticles were fabricated by dissolving PLGA (Lakeshore Biomaterials; cat. #5050 DLG4A) at 20 mg/mL in an organic solution 
Characterizing Fluorescent Microparticle Localization
In order to characterize intracellular microparticle stability, fluorescent microparticles containing the model drugs Nile Red or TRITC were administered to human primary monocytes. Thereafter, monocytes were cultured on glass chamber slides, incubated at 37˚C with media changes every 2 to 3 days. Live cells were imaged with confocal microscopy every 1-3 days. In order to identify microparticle distribution within the cells, a subset of wells was treated with TRITC microparticles on day 0, and then washed, fixed, and stained immunohistochemically on day 5 to investigate the extent of TRITC colocalization with the glucocorticoid receptor BuGR2.
Immunocytochemistry
Fluorescent immunocytochemistry was employed to determine cytoplasmic and surface marker distribution and intensity. Either on day five or day seven, cell media was removed, and cells were washed twice in 1x PBS. Washed cells were fixed in 10% 
Image Analysis of Confocal Micrographs
In order to systematically process confocal micrographs, we generated a custom MATLAB code to quantify the number and intensity of intracellular microparticles in a set of images (Sup. Fig. 1 ). Briefly, DIC and fluorescent channels were separated so that cell and microparticle channels could be processed independently. The DIC channel, containing information about the cells, was converted to a grayscale image and regions of high contrast were identified. These regions of interest were then closed by dilating and eroding the edges. Small noise was eliminated, holes within each object were filled, clusters of cells were removed, and objects on the border of the image were removed (Sup. Fig. 1 ). The remaining segmented regions of interest were considered a representative population of cells within the image. This segmentation was validated by overlaying the segmentation overtop of the original raw image. The number of pixels in each object in the cell segmentation mask was utilized to determine cell area.
Separately, the fluorescent channel was processed but analysis varied slightly depending on the experiment. For the intracellular microparticle longevity study, the fluorescent channel represented intracellular microparticles, so the channel was quantified for number of particles, particle fluorescent intensity, and total cellular fluorescent intensity (a measure of both the number of particles and particle intensity).
For the immunocytochemistry study, the fluorescent channels represented cell protein distribution, so the fluorescent channels were quantified for intensity within the cell segmentation.
Particle quantification in the particle longevity study was completed by converting the particle fluorescent channel to binary and applying a watershed transform to separate clusters of particles (Sup. Fig. 1 ). Only particles within the regions of the cell segmentation were considered. This eliminated the occasional extracellular particle and only considered intracellular particles within single cells not adjacent to the image border. The spectrophotometrically for absorbance at 241 nm, and the microparticles were resuspended in fresh 1x PBS (Sup. Fig. 2) . A Dex standard curve was made at 241 nm in warmed 1x PBS to correlate absorbance with concentration.
Enzyme-Linked Immunosorbent Assays
At regular intervals, conditioned media collected from cells was assessed with enzyme-linked immunosorbent assays (ELISA) in order to quantify the concentration of extracellular tumor necrosis factor alpha (TNFα, Invitrogen, cat. #88-7346-88) or Dex (Bioo Scientific, cat. #1112). All ELISAs were completed according to the manufacturer's instructions.
Phagocytosis Assay
Human primary monocytes were fluorescently labeled with Vybrant DiO cell- µg/mL for myelin basic protein, 1*10 7 particles/mL of E. coli, and 1*10 7 particles/mL for the polystyrene beads. Cells were allowed to incubate with the fluorescent targets at 37˚C for 6 hours. Following incubation, media was removed, cells were washed three times, and were fixed in 10% paraformaldehyde at room temperature for 20 minutes. Cells were washed two more times and then imaged on a confocal microscope (Olympus FV1000
Laser Scanning Confocal). In order to measure phagocytic uptake, images were computationally segmented, as described above, and the total fluorescence signal per cell was quantified.
RNA Extraction
Primary human monocytes were thawed and treated with nothing, free Dex, blank microparticles, or Dex microparticles and allowed to mix gently at 37˚C for four hours.
Following incubation, cells were separated from non-phagocytosed microparticles, resuspended in complete media supplemented with MCSF, and plated in ultra-low attachment plates. On days 3 and 5, media was gently removed and replaced with complete media with MCSF supplemented with inflammatory stimuli LPS and IFNγ. On day 7, media was removed, and lysis buffer was added to each well. Cell lysates were stored at -80˚C until RNA purification could be completed. RNA from human cells was cleaned and collected utilizing an RNAqueous-Micro Kit (Ambion, cat. #AM1931) according to the manufacturer's instructions. RNA concentration was quantified using a NanoDrop 1000 Spectrophotometer (V 3.8.1).
Gene Expression Analysis
Gene expression analysis was completed by using NanoString's high-throughput
PlexSet technology to assess absolute gene counts from purified RNA. A custom code set was generated and corresponding oligonucleotides probes, which bind to specific genes of interested, were fabricated through Integrated DNA Technologies. Thereafter, experimental samples, oligonucleotide probes, and NanoString reagent were added together according to the manufacturer's instructions. Absolute gene count raw data was quantified with the nCounter MAX prep station. Raw gene counts were first normalized by subtracting out the lane-spectific negative controls and then dividing by the lanespecific positive controls. Negative values were set to zero and data was transformed according to a reciprocal transform y' = 1/(y+1). The heat map presents transformed data and all statistics were completed on transformed data because transformation generated a normal distribution. However, to ease interpretation for the readers, column graphs were plotted of data prior to transformation because a reciprocal transform function would present data in a counter-intuitive manner.
Statistical Analyses
All data were statistically assessed with the appropriate parametric test. If we observed that data did not adhere to parametric data requirements, data was transformed to generate an approximately normal distribution and subsequently characterized with the appropriate parametric one-way or two-way ANOVA. P values from Tukey's Honest Significant Difference post hoc analyses were always adjusted to account for multiple comparisons. Data generated from NanoString quantification was assessed with a oneway ANOVA for each gene on transformed data. However, to simplify data interpretation, the pre-transformed data were plotted within each gene's graph.
